Zhejiang University's engineered yeast boosts cancer drug precursor 1,000x

Vinblastine, a critical chemotherapy drug, has been harvested exclusively from the Madagascar periwinkle plant for decades, requiring 2 tonnes of dried leaves to yield just 1 gram—making it pricier than gold. A cross-disciplinary collaboration between Zhejiang University (Lian Jiazhang), the University of New Brunswick (Qu Yang), and Westlake University (Wang Yajie) has now turned yeast into a microbial factory that produces the drug's direct precursor, catharanthine, at 164.9 mg/L in a fermenter. That's roughly 1,000 times higher than any previously published yield, offering a pathway to reliable, scalable production. The breakthrough, published in Science on July 16, builds on Lian's 2022 work inserting the full 30-step vinblastine synthesis pathway into yeast, though initial output was stuck at just micrograms per litre.

The key obstacle was an unstable intermediate compound within the pathway—a molecular puzzle that required advances in plant biochemistry, synthetic biology, and protein engineering to solve. By redesigning the cell's internal structure and stabilizing that intermediate, the team unlocked a dramatic 1,000-fold productivity jump. While the process still needs to be scaled to industrial volumes and extended to complete the final conversion to vinblastine, the achievement marks a significant step toward decoupling an essential cancer medication from agricultural supply chains. If scaled further, it could lower drug costs, eliminate supply variability, and make yeast-based biomanufacturing a viable alternative for other rare plant-derived medicines.